<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A phase II trial evaluated safety, feasibility and efficacy of a sequential tandem approach combining myeloablative BEAM chemotherapy and autologous stem cell transplantation (ASCT) with myeloablative radioimmunotherapy (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-RIT), with (131)I-anti-CD20 antibody ((131)I-rituximab), followed by a second ASCT in patients with relapsed or refractory CD20+ B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>According to protocol, 16 patients with relapsed (n = 14) and refractory (n = 2) CD20+ B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> received salvage therapy with rituximab and Dexa-BEAM, followed by BEAM (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> chemotherapy) and high-dose myeloablative radioimmunotherapy 2-6 months after BEAM </plain></SENT>
<SENT sid="2" pm="."><plain>Nine of 16 patients received <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-RIT; seven patients were excluded before <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-RIT because of toxicity or progressive disease </plain></SENT>
<SENT sid="3" pm="."><plain>Disease histologies were follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) grades 1 and 2 (n = 4), transformed follicular (FL 3b; n = 6), diffuse large B-cell (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>; n = 4), mantle cell (n = 1) and marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 1) </plain></SENT>
<SENT sid="4" pm="."><plain>After a median follow-up of 50.4 months for OS and 39.7 months for progression-free survival (PFS), estimated 4-year OS and PFS were 67% and 64%, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>The estimated 4-year OS and PFS for patients with FL were 80% and 78%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Toxicity was significant, including one fatal outcome due to <z:e sem="disease" ids="C0032285" disease_type="Disease or Syndrome" abbrv="PNEUM">pneumonitis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Tandem transplants consisting of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> chemotherapy followed by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-RIT with (131)I-coupled anti-CD20 are manageable and effective but toxic treatment modalities for relapsed poor prognosis CD20+ B-NHL </plain></SENT>
</text></document>